When do we need competing risks methods for survival analysis in nephrology?
Marlies Noordzij(University of Amsterdam), Kitty J. Jager(Amsterdam University Medical Centers), Karen Leffondré(Bordeaux Population Health), Karlijn J. van Stralen(Amsterdam UMC Location University of Amsterdam), Carmine Zoccali(Biogem), Friedo W. Dekker(Leiden University Medical Center)
Cited by 674
Related Papers
Obesity and Kidney Disease: Hidden Consequences of the Epidemic
|American Journal of Nephrology|2017|2.2k
Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study
|The Lancet|2001|1.1k
Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria
|The Lancet|1999|909
A single number for advocacy and communication—worldwide more than 850 million individuals have kidney diseases
|Kidney International|2019|886
An introduction to inverse probability of treatment weighting in observational research
|Clinical Kidney Journal|2021|877